At 6.3% CAGR, Asia Pacific Transient Protein Expression Market is Projected to be Worth US$ 294.26 Million by 2031, says Business Market Insights

According to Business Market Insights’ research, the Asia Pacific transient protein expression market was valued at US$ 181.05 million in 2023 and is expected to reach US$ 294.26 million by 2031, registering a CAGR of 6.3% from 2023 to 2031. Integration of artificial intelligence (AI) and automation technologies and plant-based expression systems for therapeutic protein production are among the critical factors attributed to drive the Asia Pacific transient protein expression market growth.

The integration of artificial intelligence (AI) and automation technologies into transient protein expression workflows has the potential to revolutionize the field by enhancing efficiency, accuracy, and scalability. AI algorithms can be utilized to analyze large datasets generated from transient protein expression experiments, enabling the identification of patterns and correlations that may not be readily apparent to human researchers. This data-driven approach can aid in the optimization of expression conditions, including the selection of appropriate vectors, host cells, and culture conditions, ultimately leading to improved protein yields. Moreover, AI can be leveraged to predict and model protein expression outcomes based on various input parameters, allowing for the rapid identification of optimal conditions for transient expression. By harnessing machine learning and predictive analytics, researchers can streamline the experimental design process, reduce the need for trial-and-error approaches, and accelerate the development of high-yield transient expression systems.

Furthermore, the integration of automation technologies can further enhance the efficiency of transient protein expression workflows. Automated liquid handling systems, robotic platforms, and high-throughput screening technologies can facilitate the rapid execution of complex experimental protocols, allowing for the parallel testing of multiple expression conditions. This not only expedites the optimization process but also enables the systematic exploration of a wide range of variables to identify the most favorable conditions for protein production.

Thus, the integration of AI and automation in transient protein expression will significantly enhance the scalability, reproducibility, and overall efficiency of transient protein expression systems.

On the contrary, high cost of products hampers the growth of Asia Pacific transient protein expression market.

Based on product type, the Asia Pacific transient protein expression market is segmented into instruments, reagents, expression vectors, and competent cells. The instruments segment held 35.2% market share in 2023, amassing US$ 63.71 million. It is projected to garner US$ 105.23 million by 2031 to register 6.5% CAGR during 2023–2031.

In terms of application, the Asia Pacific transient protein expression market is segmented into genomic research, gene therapy, bio production, cancer research, and drug development. The genomic research segment held 32.3% share of Asia Pacific transient protein expression market in 2023, amassing US$ 58.41 million. It is anticipated to garner US$ 101.49 million by 2031 to expand at 7.2% CAGR during 2023–2031.

Based on end user, the Asia Pacific transient protein expression market is segmented into pharmaceutical and biotechnology companies, academic and research institutes, and clinical research organizations. The pharmaceutical and biotechnology companies segment held 54.5% share of Asia Pacific transient protein expression market in 2023, amassing US$ 98.68 million. It is anticipated to garner US$ 165.02 million by 2031 to expand at 6.6% CAGR during 2023–2031.

By country, the Asia Pacific transient protein expression market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Our regional analysis states that China captured 27.4% share of Asia Pacific transient protein expression market in 2023. It was assessed at US$ 49.57 million in 2023 and is likely to hit US$ 83.19 million by 2031, registering a CAGR of 6.7% during 2023–2031.

Key players operating in the Asia Pacific transient protein expression market are Thermo Fisher Scientific Inc, Merck KGaA, QIAGEN NV, GenScript Biotech Corporation, Promega Corp, Takara Bio Inc, New England Biolabs, Agilent Technologies Inc, Mirus Bio LLC, Bio-Rad Laboratories Inc, Lonza Group AG, and MaxCyte Inc, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com